Reforms in Pharma on Snail Pace (India)
This article was originally published in PharmAsia News
India-based pharmaceutical companies are calling on government officials to reform the country's price control policy. They claim the government does not take into account the costs of packaging when establishing price restrictions on drugs. Drug manufacturers say without this consideration, it is not cost effective to produce packaging necessary to discourage the sale of substandard imitation drugs. This leaves pharmaceutical companies with a major dilemma. They can either foot the cost of packaging or risk a glut of fraudulent drugs flooding the market. Representatives for India's pharmaceutical companies worry that to avoid this quandary some manufacturers will stop making price controlled products. Unfortunately, the 75 drugs on India's price controlled list, like Iron and Vitamin A supplements, are necessary for the health of the country's population. (Click here for more
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.